case_images: PMC6042494_01
case_images: Hematoxylin and Eosin staining of a metastatic specimen in left subphrenic space by endoscopic ultrasound-guided biopsy showing small cell carcinoma.. Note: The arrow indicates that the portion of the image at the base of the arrow has been magnified by x400.
case_images: ott-11-3943Fig1.jpg
case_images: PMC6042494_01_ott-11-3943Fig1.jpg
case_images: f1-ott-11-3943
case_images: TTF-1 (+), CD56 (+), and synaptophysin (+) (Figure 1). The tumor was refractory to two cycles of cytotoxic chemotherapy and docetaxel (Figure 2).
case_images: Computed tomography (CT) images showing treatment-related changes.
case_images: ott-11-3943Fig2.jpg
case_images: PMC6042494_01_ott-11-3943Fig2.jpg
case_images: f2-ott-11-3943
case_images: TTF-1 (+), CD56 (+), and synaptophysin (+) (Figure 1). The tumor was refractory to two cycles of cytotoxic chemotherapy and docetaxel (Figure 2). After cessation of chemotherapy, her disease progressed in July 2017 (Figure 2).
case_images: Computed tomography (CT) images showing differential response to single and combined therapies.
case_images: ott-11-3943Fig3b.jpg
case_images: PMC6042494_01_ott-11-3943Fig3b.jpg
case_images: f3-ott-11-3943
case_images: The metastatic subphrenic and liver masses presented dramatic progression despite subsequent cytotoxic chemotherapy with pemetrexed or etoposide/carboplatin from July to September 2017 (Figure 3). November 2017 (Figure 3). No significant adverse effects were observed with the combination chemotherapy.